Apyx medical corporation reports third quarter 2024 financial results; updates full year 2024 financial outlook and introduces full year 2025 financial outlook

Clearwater, fla., nov. 08, 2024 (globe newswire) -- apyx medical corporation (nasdaq:apyx) (“apyx medical;” the “company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as renuvion®, today reported the financial results for its third quarter ended september 30, 2024, updated its financial expectations for the full year ending december 31, 2024, and introduced its financial expectations for the full year ending december 31, 2025.
APYX Ratings Summary
APYX Quant Ranking